BL Pharmtech

비엘팜텍 · 065170

Consumer Staples Staples Retail · KOSDAQ

Small-cap

Market cap US$35.2M (₩48.6B)

Overview

BL Pharmtech supplies health-functional foods, such as hemp seed oil and other dietary supplements, alongside a self-collection diagnostic device that allows women to test for cervical cancer and sexually transmitted diseases at home, without visiting a clinic.

Its consumer health products reach end-users through home-shopping channels and online retail platforms, while its in-vitro diagnostic device targets individual consumers directly. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three distinct divisions: consumer health foods, in-vitro diagnostic devices, and anti-cancer drug development.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$4.7M

▼ −26.1% YoY

Operating profit · FY2025

−US$2M

Loss narrowed

Net income · FY2025

−US$12.2M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$17.8M(₩24.5B)	US$6.4M(₩8.8B)	US$4.7M(₩6.5B)
Operating profit	−US$4.9M(−₩6.8B)	−US$2.3M(−₩3.2B)	−US$2M(−₩2.8B)
Net income	US$102.6K(₩141.6M)	−US$4.1M(−₩5.7B)	−US$12.2M(−₩16.8B)

Revenue

FY2023US$17.8M
FY2024US$6.4M
FY2025US$4.7M

Operating profit

FY2023−US$4.9M
FY2024−US$2.3M
FY2025−US$2M

Net income

FY2023US$102.6K
FY2024−US$4.1M
FY2025−US$12.2M

Key ratios (FY2025)

ROE

-211.8%

Debt/Eq

129.5%

Op. margin

-43.4%

Net margin

-258.0%

Rev. YoY

▼ −26.1%

Why it matters

BL Pharmtech is the largest shareholder of an affiliated company, BL Melanis, through which it conducts its anti-cancer drug pipeline development.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?